从口服葡萄糖耐受性测试中估计胰岛素敏感性和β细胞功能:验证一种新的胰岛素敏感性和分泌 (ISS) 模型
Joon Ha1, Stephanie T Chung2, Max Springer3
1Department of Mathematics, Howard University, Washington, DC.
bioRxiv : the preprint server for biology
|July 28, 2023
概括
一个新的胰岛素分泌和敏感性 (ISS) 模型通过口服葡萄糖耐受性测试准确估计胰岛素敏感性和β细胞功能. 这种务实的方法简化了2型糖尿病的研究和临床应用.
科学领域:
- 代谢生理学 代谢生理学
- 内分泌学 在内分泌学.
- 计算生物学 计算生物学
背景情况:
- 精确估计胰岛素敏感性和β细胞功能对于理解2型糖尿病 (T2D) 病原和治疗至关重要.
- 使用口服葡萄糖耐受性测试 (OGTT) 的现有方法的复杂性和准确性各不相同,有些方法需要先进的数学技能或产生非生理学结果.
研究的目的:
- 开发和验证一种新的,务实的胰岛素分泌和敏感性 (ISS) 模型,用于从标准OGTT数据中精确的SI和BCF估计.
- 为临床研究提供可靠的工具,平衡性能,可靠性和易于实施.
主要方法:
- 通过将微分方程与OGTTs的葡萄糖和胰岛素数据相匹配,开发了ISS模型,而不需要解卷或C-测量.
- 从模拟葡萄糖-胰岛素平衡和T2D进展的框架中推导出该模型.
- 在三个不同的队列中评估了ISS模型,包括患糖尿病前期高风险的个体.
主要成果:
- 国际空间站模型与黄金标准的SI和BCF估计值有很强的相关性,这些估计值来自静脉注射葡萄糖耐受性测试和高胰岛素-高血糖.
- 该模型准确地捕捉了葡萄糖-胰岛素动态的关键方面,包括肝脏葡萄糖生产抑制和双相胰岛素分泌.
结论:
- 国际空间站模型提供了一个可靠和务实的工具,用于在不同人群中表型化T2D风险.
- 其易于实施和准确性使其适合临床研究和潜在的常规临床实践.
- 这一进步有助于更深入地了解葡萄糖代谢和T2D进展.
相关概念视频
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.3K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.3K
Oral Hypoglycemic Agents: Glinides
188
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
188
Hormones Regulating Blood Glucose
3.5K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.5K
Glucagon-like Receptor Agonists
358
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
358
Insulin Secretory Vesicles
5.0K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
5.0K
Oral Hypoglycemic Agents: Biguanides and Glitazones
234
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
234


